China Resources Sanjiu: The wholly-owned subsidiary Purinergic has completed Phase III clinical trials for its sustained-release tablets.

China Resources Double-Crane announced that its wholly-owned subsidiary Double-Crane Limin's pregabalin sustained-release tablets have completed the registration release for phase III clinical trials. The trial demonstrated that the drug is effective against postherpetic neuralgia, with a rapid onset, stable long-term efficacy, and good safety profile. Double-Crane Limin will proceed with the application for drug registration. As of the announcement date, the total research and development investment for this drug amounts to 27.3547 million yuan. Currently, the drug is not yet marketed in China. The global sales figure is projected to be 77.8137 million U.S. dollars in 2025, with Jiangsu Hengrui being the only domestic approval, achieving total sales of 1.84 million yuan. The drug's research and development and market launch involve uncertainties, and the company will disclose progress in a timely manner.